elafibranor 80 MG Oral Tablet [Iqirvo]
elafibranor
RxCUI: 2684952
What the CMS Formulary Data Shows for elafibranor 80 MG Oral Tablet [Iqirvo]
Per the CMS 2026 Part D formulary file, elafibranor 80 MG Oral Tablet [Iqirvo] (RxNorm concept RXCUI 2684952, generic name elafibranor) appears on 15 distinct formulary files spanning 170 Medicare Part D plan offerings - 3.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.1.
Real-world access to elafibranor 80 MG Oral Tablet [Iqirvo] depends on utilization management as much as tier placement: 86.7% of covering formularies require prior authorization. 0% require step therapy. 86.7% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry elafibranor 80 MG Oral Tablet [Iqirvo] today.
Coverage Details
- Formularies covering
- 15
- Plans covering
- 170
- Coverage rate
- 3.4%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 86.7% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 86.7% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering elafibranor 80 MG Oral Tablet [Iqirvo]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is elafibranor 80 MG Oral Tablet [Iqirvo] covered by Medicare Part D?
Yes, elafibranor 80 MG Oral Tablet [Iqirvo] is covered by 170 Medicare Part D plans (3.4% of all Part D formularies).
What tier is elafibranor 80 MG Oral Tablet [Iqirvo] on Medicare Part D plans?
elafibranor 80 MG Oral Tablet [Iqirvo] averages Tier 4.1 across Part D plans, ranging from Tier 1 to Tier 5.
Does elafibranor 80 MG Oral Tablet [Iqirvo] require prior authorization?
86.7% of Part D formularies require prior authorization for elafibranor 80 MG Oral Tablet [Iqirvo]. Step therapy: 0%. Quantity limits: 86.7%.
Read our methodology - how this data is sourced, computed, and verified.